What is primary intensification in Kawasaki disease?

What is Primary Intensification in Kawasaki Disease?

Primary intensification in Kawasaki disease refers to the addition of adjunctive anti-inflammatory therapies (such as corticosteroids or biologics) to the standard initial treatment of IVIG and aspirin, given upfront to high-risk patients to prevent coronary artery aneurysms before IVIG resistance develops. 1

Rationale and Target Population

Primary intensification is fundamentally different from treating IVIG-resistant disease. Rather than waiting for treatment failure (persistent or recrudescent fever ≥36 hours after IVIG completion), this approach involves preemptively escalating therapy at initial presentation for patients predicted to be at high risk for:

• IVIG resistance
• Development of coronary artery aneurysms (CAAs)
• Severe disease manifestations 2, 3

The concept emerged from Japanese studies showing that 10-20% of patients fail initial IVIG therapy, and these IVIG-resistant patients have significantly higher rates of coronary complications 1.

Evidence Base

Corticosteroids as Primary Intensification

The strongest evidence for primary intensification comes from Japanese trials using corticosteroids added to initial IVIG in high-risk patients. 1

Three key Japanese studies demonstrated benefit:

• Okada et al: Single-dose pulse methylprednisolone (30 mg/kg) with IVIG in high-risk patients (Sano score) showed lower incidence of CAAs and treatment failure 1

• Egami et al/Ogata et al: Single-center RCT using methylprednisolone (30 mg/kg) with IVIG in patients at high risk by Egami score demonstrated reduced CAAs and treatment resistance 1

• RAISE Study (most robust): Multicenter RCT of 248 high-risk patients (Kobayashi score) comparing IVIG + aspirin versus IVIG + aspirin + intravenous prednisolone (2 mg/kg/day for 5 days, then oral taper). The steroid group had:

  • Lower incidence of CAAs
  • Lower treatment resistance rates
  • Lower coronary artery Z scores
  • Faster fever resolution and CRP decline 1

A meta-analysis confirmed that corticosteroid addition to standard-dose IVIG as initial treatment in high-risk patients reduced coronary artery abnormalities 1.

Critical Limitation for North American Practice

The major caveat is that Japanese risk prediction scores (Kobayashi, Egami, Sano) have low sensitivity in North American populations and cannot reliably identify high-risk patients outside Japan. 1 This severely limits the applicability of the Japanese primary intensification approach in North America, as we lack validated tools to identify which patients would benefit.

Infliximab as Primary Intensification

A 2-center, randomized, double-blind, placebo-controlled trial tested infliximab (5 mg/kg) plus IVIG versus IVIG alone in 196 patients 1. Results showed:

• No reduction in IVIG resistance rates (primary endpoint failed)
• Shortened fever duration and faster inflammatory marker normalization
• Complete prevention of IVIG infusion reactions (13% in placebo group vs 0% in infliximab group)
• Significant decrease in LAD Z score favoring infliximab
• No difference in coronary artery aneurysm rates (though underpowered for this endpoint)

Based on current evidence, addition of infliximab to initial IVIG is safe but does not prevent recrudescent fever and is not recommended for routine primary intensification. 1

Etanercept

Limited data from a small open-label study of 15 patients showed safety and acceptable pharmacokinetics, but recommendations for primary adjunctive treatment with etanercept await completion of ongoing phase III trials 1.

Current Clinical Scenarios for Primary Intensification

Based on expert practice patterns, primary intensification is most commonly considered for 4:

1. Macrophage activation syndrome (MAS) complicating KD (84% of surveyed rheumatologists use intensification)
2. KD shock syndrome (76% use intensification)
3. High risk for CAAs (52% use intensification)
4. Severe myocarditis 2

Corticosteroids are the most frequently used agent for primary intensification in these scenarios 4.

Key Clinical Pitfalls

• Do not confuse primary intensification with treatment of IVIG-resistant disease - these are distinct clinical scenarios with different timing and rationale
• Risk stratification tools validated in Japan do not work in North American populations - clinical judgment must guide decisions about primary intensification outside Japan 1
• The North American trial of single-dose pulse methylprednisolone (30 mg/kg) added to IVIG showed no overall benefit, though post-hoc analysis suggested possible benefit in highest-risk subgroups 1
• Pulsed high-dose steroid treatment is not recommended based on available evidence 1

Practical Approach

In the absence of validated North American risk scores, consider primary intensification with corticosteroids (prednisolone 2 mg/kg/day IV for 5 days followed by oral taper, based on RAISE protocol) for:

• Infants <6 months (highest risk group) 3
• KD shock syndrome
• MAS complicating KD
• Severe myocarditis
• Giant CAAs at presentation

Further research is urgently needed to develop predictive instruments for reliable identification of high-risk children outside Japan and to test optimal primary intensification regimens in these populations. 1, 5